Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mim8 in children with haemophilia A
NCT05306418Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2022
- Primary completion
- Nov 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Started Apr 2022; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05306418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306418.